For retail sale medicaments with insulin or hormones or antibiotics market in Denmark, 2026

Earlier Report Observations

The Danish market for retail-packed medicaments containing insulin, hormones, or antibiotics expanded from 2018 to 2020, with market size reaching 14 398 million $ US at its peak. This growth was driven by rising demand for insulin products, supported by an aging population and increasing diabetes prevalence, while intense competition among manufacturers spurred innovation for new preparations. After the peak, the market contracted in 2021, coinciding with a broader decline in export prices that had been falling since 2017.

Market conditions stabilized in 2022 as major producer Novo Nordisk expanded its production capacity and formed partnerships to advance early diagnosis of related metabolic diseases. A strong recovery followed in 2023, fueled by a rapid increase in imports of insulin therapeutic solutions, indicating a significant expansion of domestic demand. In 2024, the implementation of stricter clinical management guidelines reduced off-label use of certain insulin preparations, shaping the market's composition.

Throughout the period, the market structure was defined by strict price regulation ensuring uniform pharmacy pricing and the dominant role of state-influenced companies like Novo Nordisk, solidifying Denmark's position as a leading global exporter of these medicaments.

Production for retail sale medicaments with insulin or hormones or antibiotics in Denmark

In value, 2018-2021, M $ US

Denmark's production volume of retail sale medicaments containing insulin, hormones, or antibiotics declined after two years of growth. In 2021, output was valued at 10 993 million US dollars, marking a significant 21.0% decrease from the previous year. Between 2018 and 2021, production fell by 13.6%, which translates to an average annual decline of 4.7%. The peak value was recorded in 2020 at 13 910 million US dollars, following the largest annual increase of 8.4% that same year.

Annual dynamics of production in Denmark in value, 2018-2021, M $ US

Exports for retail sale medicaments with insulin or hormones or antibiotics from Denmark

Exports in kind, t

After two years of growth, Denmark's export volumes of retail sale medicaments with insulin, hormones, or antibiotics declined. In 2021, export volume reached 483 tonnes, showing a substantial contraction of 20.4% compared to the previous year. Between 2018 and 2021, exports increased by 52.8%, averaging an annual growth rate of 15.2%. The highest volume was recorded in 2020 at 607 tonnes, following the largest annual increase of 47.2% in 2019.

Annual dynamics of product's exports from Denmark in kind, 2018-2021, t

From 2018 to 2021, Denmark's exports of retail sale medicaments containing insulin, hormones, or antibiotics were widely distributed across partner countries. Sweden accounted for 16.4% of exports in kind, Poland for 13.0%, and the Netherlands for 10.6%. Together, these three countries represented only 40.0% of total export flows, indicating a diverse market structure.

Structure of product's exports in kind by countries, 2018-2021

World map of product's exports from Denmark in kind, 2018-2021

Exports in value, M $ US

Denmark's exports of retail sale medicaments with insulin, hormones, or antibiotics increased for the third consecutive year. In 2021, exports totalled 111 million US dollars, which is 1.6% higher than the previous year. Between 2018 and 2021, exports grew by 72.9%, equating to an average annual rate of 20.0%.

Annual dynamics of product's exports from Denmark in value, 2018-2021, M $ US

From 2018 to 2021, Sweden, Poland, and the Netherlands were the largest buyers of Denmark's retail sale medicaments containing insulin, hormones, or antibiotics in value terms. Sweden accounted for 19.5% of exports, Poland for 15.0%, and the Netherlands for 8.7%. However, their combined contribution was limited to 43.1% of total export value, reflecting a diversified country structure.

Structure of product's exports in value by countries, 2018-2021

World map of product's exports from Denmark in value, 2018-2021

Imports for retail sale medicaments with insulin or hormones or antibiotics to Denmark

Imports in kind, t

Denmark's imports of retail sale medicaments with insulin, hormones, or antibiotics increased for the third consecutive year. In 2021, imports reached 19 621 tonnes, representing a gain of 84.3% from the previous year. Over the period from 2018 to 2021, imports surged by 1 211.2%, with a compound annual growth rate of 135.8%.

Annual dynamics of product's imports to Denmark in kind, 2018-2021, t

Throughout 2018 to 2021, Denmark's imports in kind of retail sale medicaments containing insulin, hormones, or antibiotics were entirely concentrated in Special Categories, which accounted for 100.0% of total import flows.

Structure of product's imports in kind by countries, 2018-2021

World map of product's imports to Denmark in kind, 2018-2021

Imports in value, M $ US

Denmark's imports of retail sale medicaments with insulin, hormones, or antibiotics increased for the third consecutive year. In 2021, imports totalled 1 165 million US dollars, showing an abrupt gain of 95.1% relative to the prior year. Between 2018 and 2021, imports increased by 588.1%, equating to an average annual rate of 90.2%.

Annual dynamics of product's imports to Denmark in value, 2018-2021, M $ US

From 2018 to 2021, the partner base for Denmark's imports in value terms of retail sale medicaments containing insulin, hormones, or antibiotics was extremely narrow, with Special Categories alone responsible for 100.0% of total import flows.

Structure of product's imports in value by countries, 2018-2021

World map of product's imports to Denmark in value, 2018-2021